IL273574B2 - Inflammatory biomarkers for predicting response to FGF-18 compound - Google Patents

Inflammatory biomarkers for predicting response to FGF-18 compound

Info

Publication number
IL273574B2
IL273574B2 IL273574A IL27357420A IL273574B2 IL 273574 B2 IL273574 B2 IL 273574B2 IL 273574 A IL273574 A IL 273574A IL 27357420 A IL27357420 A IL 27357420A IL 273574 B2 IL273574 B2 IL 273574B2
Authority
IL
Israel
Prior art keywords
fgf
treatment
compound
subject
cartilage
Prior art date
Application number
IL273574A
Other languages
English (en)
Hebrew (he)
Other versions
IL273574A (en
IL273574B1 (en
Inventor
Hans Guehring
Christoph H Ladel
Anne-Christine Bay-Jensen
Morten Karsdal
Per Qvist
Original Assignee
Merck Patent Gmbh
Hans Guehring
Christoph H Ladel
Bay Jensen Anne Christine
Morten Karsdal
Per Qvist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Hans Guehring, Christoph H Ladel, Bay Jensen Anne Christine, Morten Karsdal, Per Qvist filed Critical Merck Patent Gmbh
Publication of IL273574A publication Critical patent/IL273574A/en
Publication of IL273574B1 publication Critical patent/IL273574B1/en
Publication of IL273574B2 publication Critical patent/IL273574B2/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL273574A 2017-09-29 2018-09-28 Inflammatory biomarkers for predicting response to FGF-18 compound IL273574B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17194169 2017-09-29
EP18169317 2018-04-25
PCT/EP2018/076391 WO2019063756A1 (en) 2017-09-29 2018-09-28 INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND

Publications (3)

Publication Number Publication Date
IL273574A IL273574A (en) 2020-05-31
IL273574B1 IL273574B1 (en) 2024-09-01
IL273574B2 true IL273574B2 (en) 2025-01-01

Family

ID=63722379

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273574A IL273574B2 (en) 2017-09-29 2018-09-28 Inflammatory biomarkers for predicting response to FGF-18 compound

Country Status (16)

Country Link
US (2) US11467169B2 (enExample)
EP (1) EP3688468B1 (enExample)
JP (1) JP7418324B2 (enExample)
CN (1) CN111164429B (enExample)
AU (1) AU2018343980B2 (enExample)
CA (1) CA3075713A1 (enExample)
DK (1) DK3688468T3 (enExample)
ES (1) ES2918249T3 (enExample)
HR (1) HRP20220737T1 (enExample)
HU (1) HUE058848T2 (enExample)
IL (1) IL273574B2 (enExample)
LT (1) LT3688468T (enExample)
PL (1) PL3688468T3 (enExample)
RS (1) RS63292B1 (enExample)
SI (1) SI3688468T1 (enExample)
WO (1) WO2019063756A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107209177A (zh) 2015-01-29 2017-09-26 阿雷斯贸易股份有限公司 用于高正电荷蛋白的免疫测定法
CN111164429B (zh) 2017-09-29 2024-08-09 默克专利有限公司 预测对fgf-18化合物反应性的炎性生物标志物
CN111163791A (zh) 2017-09-29 2020-05-15 默克专利有限公司 预测对fgf-18化合物反应性的代谢生物标志物
HRP20240665T1 (hr) 2018-09-10 2024-08-16 Merck Patent Gmbh Markeri korisni u strategijama obogaćivanja za liječenje osteoartritisa

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023703A1 (en) * 2012-08-06 2014-02-13 Ares Trading S.A. Genetic markers for predicting responsiveness to fgf-18 compound

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9712348B1 (pt) 1996-10-16 2013-06-18 vetor de expressão, célula de bactéria ou levedura transformada ou transfectada, processo para produzir um polipeptídeo homólogo de fgf, composição farmacêutica, e, processos para estimular ex vivo células progenitoras de miócitos ou miócitos
JP4754823B2 (ja) 2002-10-07 2011-08-24 ザイモジェネティクス, インコーポレイテッド Fgf18の投与方法
CA2502926A1 (en) 2002-11-08 2004-05-27 Linda J. Sandell Uncoupled collagen synthesis and degradation assays
AU2005314438B2 (en) 2004-12-10 2012-03-29 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
US8224579B2 (en) 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
AR062522A1 (es) 2006-08-25 2008-11-12 Ares Trading Sa Tratamiento de desordenes en cartilagos
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
US20100098775A1 (en) 2008-05-02 2010-04-22 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
WO2014023704A1 (en) 2012-08-06 2014-02-13 xARES TRADING S.A. Prognosis biomarkers in cartilage disorders
WO2015084883A2 (en) 2013-12-02 2015-06-11 Abbvie, Inc. Compositions and methods for treating osteoarthritis
CN106029085B (zh) 2013-12-24 2020-08-04 阿雷斯贸易股份有限公司 木糖葡聚糖凝胶中的fgf-18制剂
SG11201604972TA (en) 2013-12-24 2016-07-28 Ares Trading Sa Fgf-18 formulation in alginate/collagen hydrogels
MX2016010872A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
LT3107592T (lt) 2014-02-20 2018-12-10 Merck Patent Gmbh Implantas, apimantis fgf-18
EP3107591B1 (en) 2014-02-20 2018-04-18 Merck Patent GmbH Fgf-18 in graft transplantation and tissue engineering procedures
CN107209177A (zh) 2015-01-29 2017-09-26 阿雷斯贸易股份有限公司 用于高正电荷蛋白的免疫测定法
CN108473491A (zh) 2015-11-06 2018-08-31 萨穆梅德有限公司 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
CN111164429B (zh) 2017-09-29 2024-08-09 默克专利有限公司 预测对fgf-18化合物反应性的炎性生物标志物
CN111163791A (zh) 2017-09-29 2020-05-15 默克专利有限公司 预测对fgf-18化合物反应性的代谢生物标志物
HRP20240665T1 (hr) 2018-09-10 2024-08-16 Merck Patent Gmbh Markeri korisni u strategijama obogaćivanja za liječenje osteoartritisa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023703A1 (en) * 2012-08-06 2014-02-13 Ares Trading S.A. Genetic markers for predicting responsiveness to fgf-18 compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SIEBUHR ET AL,, SEROLOGICAL IDENTIFICATION OF FAST PROGRESSORS OF STRUCTURAL DAMAGE WITH RHEUMATOID ARTHRITIS, 14 August 2013 (2013-08-14) *
SIEBUHR ET AL., IDENTIFICATION AND CHARACTERISATION OF OSTEOARTHRITIS PATIENTS WITH INFLAMMATION DERIVED TISSUE TURNOVER, 31 January 2014 (2014-01-31) *

Also Published As

Publication number Publication date
CN111164429B (zh) 2024-08-09
HRP20220737T1 (hr) 2022-09-02
RS63292B1 (sr) 2022-06-30
US11467169B2 (en) 2022-10-11
DK3688468T3 (da) 2022-06-20
EP3688468A1 (en) 2020-08-05
CA3075713A1 (en) 2019-04-04
LT3688468T (lt) 2022-06-27
EP3688468B1 (en) 2022-03-16
US20210231680A1 (en) 2021-07-29
ES2918249T3 (es) 2022-07-14
US12332250B2 (en) 2025-06-17
US20230258659A1 (en) 2023-08-17
IL273574A (en) 2020-05-31
JP2020535423A (ja) 2020-12-03
JP7418324B2 (ja) 2024-01-19
AU2018343980A1 (en) 2020-04-02
HUE058848T2 (hu) 2022-09-28
AU2018343980B2 (en) 2025-04-10
WO2019063756A1 (en) 2019-04-04
PL3688468T3 (pl) 2022-07-18
SI3688468T1 (sl) 2022-08-31
CN111164429A (zh) 2020-05-15
IL273574B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
US12332250B2 (en) Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
US12332251B2 (en) Metabolic biomarkers for predicting responsiveness to FGF-18 compound
US12383603B2 (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829A (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829B (en) Markers useful in enrichment strategies for the treatment of osteoarthritis